March 21, 2017 09:03 AM EDT

Struggling Heat gets a warm response to a snapshot on cancer vax data

Arsalan Arif

Founder

Heat Biologics managed to at least temporarily extricate itself from penny stock territory after offering a positive update on its combination study for non …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Struggling Heat gets a warm response to a snapshot on cancer vax data

Arsalan Arif

Founder

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Strug­gling Heat gets a warm re­sponse to a snap­shot on can­cer vax da­ta

Arsalan Arif

Founder

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Struggling Heat gets a warm response to a snapshot on cancer vax data

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout